Lisata Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
MAR001 showed substantial triglyceride reductions without a glucose signal in phase IIb; confirmatory sHTG data and MAR005 dose selection are expected in 2027. MAR002 phase II data are also expected in 2027, ahead of planned phase III initiation in H1 2028.
-
TIMI 78 showed baseline-linked triglyceride reductions, reaching 70%-72% at high dose in patients above 500 mg/dL, with no glucose increase signal. 2027 brings Phase II catalysts in both programs; the $225M PIPE is expected to fund operations through mid-2028 and enable both Phase III starts.
Fiscal Year 2025
-
Certepetide development advanced with positive clinical data across multiple cancer trials and new strategic partnerships. Operating expenses and net loss decreased year-over-year, with a cash runway into Q1 2027, excluding phase III costs. Final pivotal trial data and further business milestones are expected in 2026.
-
A novel peptide adjuvant is showing significant survival and response improvements in solid tumor cancers, especially metastatic pancreatic cancer, with broad compatibility and no added toxicity. Multiple strategic partnerships, regulatory designations, and a strong financial position support ongoing and future clinical milestones.
-
Q2 2025 saw reduced expenses and a narrowed net loss, with $22M in cash supporting operations into Q4 2026. Multiple clinical milestones were achieved, including positive preliminary data for Certepetide and new strategic partnerships, while a key patent extended exclusivity to 2040.
-
Q1 2025 saw reduced expenses and net loss, with $25.8M in cash supporting operations into Q3 2026. Certepetide clinical programs advanced, with key trial data and milestones expected in the next 12โ18 months. Multiple collaborations and licensing deals expand pipeline reach.
Fiscal Year 2024
-
Advanced clinical programs for certepetide in solid tumors showed positive early data, with 2024 financials reflecting reduced expenses and a strong cash position. Multiple key trial readouts and milestones are expected in 2025, supporting further development and potential partnerships.
-
Sirtepotide development advanced in multiple cancer types and endometriosis, with key clinical milestones and data readouts expected in 2025. Operating expenses and net loss decreased year-over-year, and current capital is projected to fund operations into early 2026.
-
A novel peptide platform is advancing in late-stage clinical trials for solid tumors, showing improved survival and efficacy in both preclinical and clinical settings. Multiple regulatory designations, strategic partnerships, and a strong financial position support upcoming milestones through 2026.
-
Certepetide clinical development advanced with multiple global trials, regulatory designations, and strong financial management. Key data readouts are expected in late 2024 and 2025, with cash reserves projected to fund operations into early 2026.